The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The logic for a placing is that thought eggy. You’ve got to ask the question if they are going for it now, why? Is it cause they want the sticky II protection for data and deals inbound to guard against a low ball offer? They are cashed up to the back end of the year, perhaps the company needs this protection sooner?
Results could be so good that the attitude is just crack on, we’ll sort out various dosing levels and intervals further down the road. The FDA seem quite proactive when it comes to saving lives, and this is what this is all about. Anyhow, not what I think will happen, but it could
So if we’re going to go down the avenue of ‘ifs’, what if the results on first line patients in C7 have been so good that the fortnightly dosing has been scrapped and it’s straight into P2? Might explain the need for funding but ‘if’ that news drops where would that leave the shorting crew!!
They might bring healthcare investors onboard before releasing game changing data and license deals. They get in cheap. We get protection from lowball offers, but also, once data and deals land, share price can appreciate as funding is also secured
The funding is required for p2 and ava3996 ind, and ongoing general business costs. They have funding until the back end of this year. It’s probably also wise to have a decent balance sheet whilst negotiating license deals for your tech with other companies to avoid lowball deal offers. There isn’t a panic as yet but as the company have said they are always considering their options. I personally feel an II to firm up the share register so when data drops we are funded and protected from low ball takeover offers.